Nine weeks versus 1 year adjuvant trastuzumab in combination with

Trastuzumab and pertuzumab trastuzumab In 2006, trastuzumab plus chemotherapy was approved to treat patients after their HER2-overexpressing breast tumors were surgically removed trastuzumab Trastuzumab is a biologic therapy indicated for the treatment of human epidermal growth factor receptor 2 -positive breast cancer and

trastuzumab Trastuzumab is a biologic antineoplastic agent that, at the time of its FDA approval in 1998, was among the first available targeted chemotherapies